A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Amgen
- 03 Nov 2017 Planned End Date changed from 22 Oct 2022 to 4 Nov 2022.
- 03 Nov 2017 Planned primary completion date changed from 22 Oct 2022 to 4 Nov 2022.
- 03 Nov 2017 Status changed from recruiting to active, no longer recruiting.